TALARIS THERAPEUTICS INC (TALS) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:TALS • US87410C1045

2.72 USD
-0.02 (-0.73%)
At close: Oct 19, 2023
2.75 USD
+0.03 (+1.1%)
After Hours: 10/19/2023, 8:10:51 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to TALS. TALS was compared to 524 industry peers in the Biotechnology industry. TALS has a great financial health rating, but its profitability evaluates not so good. TALS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • TALS had negative earnings in the past year.
  • TALS had a negative operating cash flow in the past year.
TALS Yearly Net Income VS EBIT VS OCF VS FCFTALS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -20M -40M -60M

1.2 Ratios

  • With a Return On Assets value of -46.99%, TALS perfoms like the industry average, outperforming 51.00% of the companies in the same industry.
  • TALS's Return On Equity of -50.38% is fine compared to the rest of the industry. TALS outperforms 64.29% of its industry peers.
Industry RankSector Rank
ROA -46.99%
ROE -50.38%
ROIC N/A
ROA(3y)-24.01%
ROA(5y)N/A
ROE(3y)-25.36%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TALS Yearly ROA, ROE, ROICTALS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 -10 -20 -30 -40

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for TALS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TALS Yearly Profit, Operating, Gross MarginsTALS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022

More info and screens

8

2. Health

2.1 Basic Checks

  • The number of shares outstanding for TALS has been increased compared to 1 year ago.
  • TALS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TALS Yearly Shares OutstandingTALS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 10M 20M 30M 40M
TALS Yearly Total Debt VS Total AssetsTALS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

  • An Altman-Z score of 4.50 indicates that TALS is not in any danger for bankruptcy at the moment.
  • TALS has a better Altman-Z score (4.50) than 81.89% of its industry peers.
  • There is no outstanding debt for TALS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.5
ROIC/WACCN/A
WACCN/A
TALS Yearly LT Debt VS Equity VS FCFTALS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 100M 200M

2.3 Liquidity

  • A Current Ratio of 15.41 indicates that TALS has no problem at all paying its short term obligations.
  • TALS's Current ratio of 15.41 is amongst the best of the industry. TALS outperforms 87.38% of its industry peers.
  • A Quick Ratio of 15.41 indicates that TALS has no problem at all paying its short term obligations.
  • TALS has a Quick ratio of 15.41. This is amongst the best in the industry. TALS outperforms 87.38% of its industry peers.
Industry RankSector Rank
Current Ratio 15.41
Quick Ratio 15.41
TALS Yearly Current Assets VS Current LiabilitesTALS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

  • TALS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.79%, which is quite impressive.
EPS 1Y (TTM)24.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 9.08% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y22.08%
EPS Next 2Y18.99%
EPS Next 3Y3.04%
EPS Next 5Y9.08%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TALS Yearly Revenue VS EstimatesTALS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 100M 200M 300M
TALS Yearly EPS VS EstimatesTALS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TALS. In the last year negative earnings were reported.
  • Also next year TALS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TALS Price Earnings VS Forward Price EarningsTALS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TALS Per share dataTALS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.99%
EPS Next 3Y3.04%

More info and screens

4

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 55.58%, TALS is a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 1.12, TALS pays a better dividend. On top of this TALS pays more dividend than 99.83% of the companies listed in the same industry.
  • TALS's Dividend Yield is rather good when compared to the S&P500 average which is at 1.83.
Industry RankSector Rank
Dividend Yield 55.58%

5.2 History

  • TALS does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
TALS Yearly Dividends per shareTALS Yearly Dividends per shareYearly Dividends per share 2023 0.5 1 1.5

5.3 Sustainability

DPN/A
EPS Next 2Y18.99%
EPS Next 3Y3.04%
TALS Yearly Income VS Free CF VS DividendTALS Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2019 2020 2021 2022 -20M -40M -60M

More info and screens

TALARIS THERAPEUTICS INC

NASDAQ:TALS (10/19/2023, 8:10:51 PM)

After market: 2.75 +0.03 (+1.1%)

2.72

-0.02 (-0.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14
Earnings (Next)11-08
Inst Owners0%
Inst Owner Change0%
Ins Owners11.37%
Ins Owner Change0%
Market Cap116.44M
Revenue(TTM)N/A
Net Income(TTM)-74.77M
Analysts43.33
Price Target20.4 (650%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 55.58%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-51.26%
Min EPS beat(2)-51.26%
Max EPS beat(2)-51.26%
EPS beat(4)2
Avg EPS beat(4)-12.68%
Min EPS beat(4)-51.26%
Max EPS beat(4)11.96%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)60%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.78
P/tB 0.78
EV/EBITDA N/A
EPS(TTM)-1.79
EYN/A
EPS(NY)-1.05
Fwd EYN/A
FCF(TTM)-1.4
FCFYN/A
OCF(TTM)-1.38
OCFYN/A
SpS0
BVpS3.47
TBVpS3.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -46.99%
ROE -50.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-24.01%
ROA(5y)N/A
ROE(3y)-25.36%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 95.92%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.41
Quick Ratio 15.41
Altman-Z 4.5
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)299.29%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.65%
EPS Next Y22.08%
EPS Next 2Y18.99%
EPS Next 3Y3.04%
EPS Next 5Y9.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-2.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.82%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-50.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-52.19%
OCF growth 3YN/A
OCF growth 5YN/A

TALARIS THERAPEUTICS INC / TALS FAQ

Can you provide the ChartMill fundamental rating for TALARIS THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to TALS.


What is the valuation status for TALS stock?

ChartMill assigns a valuation rating of 0 / 10 to TALARIS THERAPEUTICS INC (TALS). This can be considered as Overvalued.


What is the profitability of TALS stock?

TALARIS THERAPEUTICS INC (TALS) has a profitability rating of 1 / 10.


What is the financial health of TALARIS THERAPEUTICS INC (TALS) stock?

The financial health rating of TALARIS THERAPEUTICS INC (TALS) is 8 / 10.